EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)Multizentrische StudieOpen Access · CC BY-NC 4.0

An Integrated Nonclinical and Clinical Risk Assessment of the Effects of Investigational ATRi Tuvusertib on QTc Interval in Patients With Solid Tumors

Jatinder Kaur Mukker iD, Timothy A Yap iD, Anthony W Tolcher iD, Johann S de Bono iD, Ruth Plummer iD, Gary Grosser iD, Christoph van Amsterdam iD, Hanno Schieferstein iD, Han Witjes iD, Paul Matthias Diderichsen iD, Axel Krebs-Brown iD, Wei Gao iD und 4 weitere

Clinical and Translational Science · 2026

DOI: 10.1111/cts.70496 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift Clinical and Translational Science, 2026. Verfasst von Jatinder Kaur Mukker und 15 weiteren Autor:innen. Beteiligte Einrichtung: EMD Serono, Billerica, Massachusetts, USA. Hauptthemen laut MEDLINE: Long QT Syndrome, Neoplasms, Protein Kinase Inhibitors. Die Arbeit nennt 37 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Tuvusertib is an investigational, orally administered inhibitor of ATR protein kinase, currently in Phase II clinical development. Here, we present an integrated nonclinical and clinical assessment of the effect of tuvusertib on QTc interval. In vitro inhibition by tuvusertib of the hERG potassium channel was evaluated, and in vivo ECG assessments evaluated the effect on QTc in dogs. PK‐matched triplicate ECGs in patients receiving tuvusertib in Part A1 of the Phase I DDRiver Solid Tumors 301 study ( N = 55; dosing regimens: 5–270 mg QD, 180–220 mg QD 2 weeks on/1 week off, or 150 mg BID 4 days on/3 days off) contributed to concentration‐QTc analyses via linear mixed‐effects modeling. In vitro, tuvusertib inhibited hERG with an IC 50 of 2.83 μM, which is ~2.5 times its steady‐state unbound C max at the clinical RDE (180 mg QD 2 weeks on/1 week off). In vivo, tuvusertib did not affect QTc up to 5 mg/kg/day in dogs (unbound C max comparable to that at clinical RDE). In patients with advanced solid tumors receiving tuvusertib at up to threefold higher plasma concentrations than at the RDE, the risk for clinically relevant QTc prolongation was assessed to be low (upper limit of 90% CI of model‐predicted ΔQTcF < 20 ms). There was no relationship between tuvusertib plasma concentration and RR interval, suggesting no effect on HR. Early integrated concentration‐QTc assessments of tuvusertib monotherapy in Phase I were crucial in informing the low risk for clinically relevant QTc prolongation, thereby facilitating efficient evaluation of investigational tuvusertib combination strategies in ongoing clinical development.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Long QT SyndromeNeoplasmsProtein Kinase InhibitorsAdultAgedAnimalsDogsFemaleHumansMaleMiddle AgedElectrocardiographyERG1 Potassium ChannelRisk Assessment

Stichwörter der Autor:innen

QTc intervalcancerscardiovascular riskclinical trialsexposure responseoncologyphase 1

Substanzen

ERG1 Potassium ChannelKCNH2 protein, humanProtein Kinase Inhibitors

Autor:innen und Institutionen

  • EMD Serono, Billerica, Massachusetts, USA.
  • University of Texas MD Anderson Cancer Center, Houston, Texas, USA.
  • New Experimental Therapeutics (NEXT), San Antonio, Texas, USA.
  • Royal Marsden Hospital, Sutton, UK.
  • Newcastle University and Northern Centre for Cancer Care, Newcastle Hospitals NHS Trust, Newcastle upon Tyne, UK.
  • the healthcare business of Merck KGaA, Darmstadt, Germany.

ORCID-Profile: Jatinder Kaur Mukker, Timothy A Yap, Anthony W Tolcher, Johann S de Bono, Ruth Plummer, Gary Grosser, Christoph van Amsterdam, Hanno Schieferstein, Han Witjes, Paul Matthias Diderichsen, Axel Krebs-Brown, Wei Gao, Rainer Strotmann, Zoltan Szucs, Ioannis Gounaris, Karthik Venkatakrishnan

Zitieren

APA

Mukker, J. K., Yap, T. A., Tolcher, A. W., de Bono, J. S., Plummer, R., Grosser, G., van Amsterdam, C., Schieferstein, H., Witjes, H., Diderichsen, P. M., Krebs-Brown, A., Gao, W., Strotmann, R., Szucs, Z., Gounaris, I., & Venkatakrishnan, K. (2026). An Integrated Nonclinical and Clinical Risk Assessment of the Effects of Investigational ATRi Tuvusertib on QTc Interval in Patients With Solid Tumors. Clinical and Translational Science. https://doi.org/10.1111/cts.70496

Vancouver

Mukker JK, Yap TA, Tolcher AW, de Bono JS, Plummer R, Grosser G, et al. An Integrated Nonclinical and Clinical Risk Assessment of the Effects of Investigational ATRi Tuvusertib on QTc Interval in Patients With Solid Tumors. Clinical and Translational Science. 2026. doi:10.1111/cts.70496

BibTeX
@article{Mukker2026,
  author = {Mukker, Jatinder Kaur and Yap, Timothy A and Tolcher, Anthony W and de Bono, Johann S and Plummer, Ruth and Grosser, Gary and van Amsterdam, Christoph and Schieferstein, Hanno and Witjes, Han and Diderichsen, Paul Matthias and Krebs-Brown, Axel and Gao, Wei and Strotmann, Rainer and Szucs, Zoltan and Gounaris, Ioannis and Venkatakrishnan, Karthik},
  title = {An Integrated Nonclinical and Clinical Risk Assessment of the Effects of Investigational ATRi Tuvusertib on QTc Interval in Patients With Solid Tumors},
  journal = {Clinical and Translational Science},
  year = {2026},
  doi = {10.1111/cts.70496}
}
Kostenlos starten →